Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
about
Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicityFVIII inhibitors: pathogenesis and avoidanceAntidrug Antibodies: B Cell Immunity Against TherapyClassification and characterization of therapeutic antibody aggregates.Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia.Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy.Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responsesNeutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentCharacterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.Acquired Factor VIII Inhibitors: Three Cases.Role of regulatory T cells in tolerance to coagulation factors.Immune tolerance induction in haemophilia: evidence and the way forward.The reversal of inhibitors in congenital hemophilia.Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic miceIgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.The EPIC study: a lesson to learn.Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality.IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors.Spectrum of Molecular Defects in 216 Chinese Families With Hemophilia A: Identification of Noninversion Mutation Hot Spots and 42 Novel Mutations.Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.Identification of factor VIII gene mutations in patients with severe haemophilia A in Venezuela: identification of seven novel mutations.Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.Vaccinations are not associated with inhibitor development in boys with severe haemophilia A.Allergenic vaccines administration and inhibitor development in haemophilia.Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants.
P2860
Q26866323-E5144C06-E4B8-4EC3-9EE6-0106DF618A50Q27027224-20DA2EB4-74EE-441D-8E60-CF7405B77616Q28082303-5D8152EE-E95A-44AC-9A5E-6D4973476D69Q30502491-0B6D28EB-1098-41B3-8346-2B5EA393DE5FQ33417625-AE012FA6-9CF9-4AC0-A699-293BF41D40DCQ34541550-4A8662D1-38D2-4582-B562-58DA54C5E3F3Q36126960-5AF852BF-3045-4BFB-90D4-3AA980C64539Q36338254-3846A3E2-1196-4E58-AA20-C91651EF5493Q36586264-1514B096-B8DA-4B9C-9206-3AC0645B1914Q37193965-E5FA5920-65C4-408D-AE3F-645A63F78308Q37561470-73946446-9114-49CB-838A-0B6415AB2DC1Q37903944-0B23D0A3-9948-4032-BB9E-D231E7FD1FC0Q38077139-0F5F24A7-2A56-4E44-9F0F-E804FAE1C599Q39084223-B086273A-DEF6-4455-A764-111F92F8F025Q40086660-392EB466-FCC1-4665-82B1-B5BB3E2C1640Q41014168-16A67489-EEDF-4520-B1B5-784EE5CE7AA2Q41732261-E080DBE2-066B-4D7A-B28F-69288066CCCDQ41963402-628D01C8-4093-4033-A0A5-6858EB59E9E5Q43218590-8BA65D6F-0975-4104-A089-1549FE67DB0BQ44988735-C5B1069C-00A7-4318-9077-120278E1E31EQ45863386-CE589B9C-B72C-436D-AF58-8DD1F8587B59Q45864935-07856010-BD1F-4A16-96BA-58F8D1C1979BQ45867958-72F1D7FF-AEF0-4BC8-AD88-8072D23093A5Q45873592-8E9DF6F2-95B1-40B3-A1DA-8F5BF9266D3FQ45875860-66983C33-2F7A-405A-B79F-9C7D77C1A3A4Q45879561-CFD2AED3-DE8D-40CB-AFBD-C6ECBDE01FE1Q45886106-2A89BBF4-EB9C-4975-9C21-6D2D68508572Q46612929-4D84839E-6AD9-4977-9839-9D9A8A182EB6
P2860
Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@ast
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@en
type
label
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@ast
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@en
prefLabel
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@ast
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@en
P2093
P2860
P921
P1476
Mechanisms of action of immune ...... A and factor VIII inhibitors.
@en
P2093
Birgit M Reipert
Christina Hausl
Hans-Peter Schwarz
Pauline M W van Helden
P2860
P356
10.1111/J.1365-2141.2006.06359.X
P407
P577
2007-01-01T00:00:00Z